Arvinas (ARVN) EBIT Growth (3y) (2020 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EBIT Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -18.82% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 81.27% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | 61.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.34% |
| Mar 31, 2026 | 10.06% |
| Dec 31, 2025 | 0.44% |
| Sep 30, 2025 | 12.01% |
| Jun 30, 2025 | -2.81% |
| Mar 31, 2025 | 47.93% |
| Dec 31, 2024 | -7.01% |
| Sep 30, 2024 | -8.43% |
| Jun 30, 2024 | 2.23% |
| Mar 31, 2024 | -25.94% |
| Dec 31, 2023 | -61.62% |
| Sep 30, 2023 | -32.53% |
| Jun 30, 2023 | -41.23% |
| Mar 31, 2023 | -55.31% |
| Dec 31, 2022 | -49.14% |
| Sep 30, 2022 | -139.17% |
| Jun 30, 2022 | -52.85% |
| Mar 31, 2022 | -53.95% |
| Dec 31, 2021 | -41.00% |
| Sep 30, 2021 | -49.84% |